These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24803078)

  • 21. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
    Beck M; Michel B; Rybarczyk-Vigouret MC; Levêque D; Sordet C; Sibilia J; Velten M;
    BioDrugs; 2016 Dec; 30(6):585-592. PubMed ID: 27848166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
    Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
    J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicians' perceptions of the uptake of biosimilars: a systematic review.
    Sarnola K; Merikoski M; Jyrkkä J; Hämeen-Anttila K
    BMJ Open; 2020 May; 10(5):e034183. PubMed ID: 32371511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
    Chapman SR; Fitzpatrick RW; Aladul MI
    BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
    Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
    [No Abstract]   [Full Text] [Related]  

  • 28. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
    Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
    Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
    Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provider and patient knowledge gaps on biosimilars: insights from surveys.
    Gibofsky A; Evans C; Strand V
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S227-S233. PubMed ID: 36493396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
    Barcina Lacosta T; Vulto AG; Huys I; Simoens S
    Front Med (Lausanne); 2022; 9():1029040. PubMed ID: 36703896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.
    Rieger C; Dean JA; Hall L; Vasquez P; Merlo G
    BioDrugs; 2024 Jul; 38(4):541-555. PubMed ID: 38879730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
    Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
    Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
    Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A
    BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
    Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I
    BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
    Berreur B; Guerin F; Christophe B; Limido G; Paubel P
    Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
    Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
    Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.